News

Genetic testing of patients with symptoms suggesting Alport syndrome could help doctors make a definitive diagnosis, a study reports. The tests could also identify genetic errors associated with the disease, helping doctors and patients manage it better. Researchers published their study in the Journal of Medical Genetics. It was titled “…

Reata Pharmaceuticals has enrolled the first patient in the Phase 3 portion of a clinical trial evaluating bardoxolone methyl as a treatment for chronic kidney disease stemming from Alport syndrome. The syndrome is characterized by progressive kidney failure that can lead to chronic kidney disease, or CKD. About half…

Alport syndrome (AS) patients lose specialized kidney cells, called podocytes, 11 times faster than healthy people, according to a new study. The phenomenon seems to underlie disease progression and can potentially be used as a marker for disease progression and response to treatment. The study, “Accelerated podocyte detachment and progressive…

Reata Pharmaceuticals is expecting $115.9 million revenue from the public offering of some of its stock shares, which will support the clinical development of the company’s leading investigational therapy, bardoxolone methyl, for chronic kidney disease (CKD) caused by Alport syndrome. Bardoxolone is being tested in the Phase 2/3 trial, Cardinal (NCT03019185), currently recruiting…

The Phase 2 portion of a clinical trial exploring Reata Pharmaceuticals’ bardoxolone methyl in patients with chronic kidney disease caused by Alport syndrome showed convincing results, allowing researchers to launch the Phase 3 part of the study. The CARDINAL Phase 2/3 trial has so far recruited 30 patients in…

A significant number of patients with a family history of kidney disease that was difficult to diagnose have autosomal dominant Alport syndrome, according to a study from Japan. The study, published in the journal Nephrology, suggests that genetic testing is crucial in patients with familial kidney disease who are difficult…

Diana Zippay, from Monongahela, Pennsylvania, and diagnosed with Alport Syndrome, recently announced on her Facebook page that she has found a lifesaving kidney donor and soon will receive the transplant that will give her a second chance at life. Zippay said she found a donor through the United Network…

An imbalance in protein-related processes in the body is behind a variety of kidney diseases, including Alport syndrome, a top Korean researcher argues. But his arguments don’t shed new light about the mechanisms leading to Alport, or insights that might lead to new treatments for the progressive disease. The hypothesis, which…

Bardoxolone methyl, an investigational treatment for kidney damage associated with Alport syndrome, has been granted orphan drug status by the U.S. Food and Drug Administration (FDA), Reata Pharmaceuticals announced. Bardoxolone methyl (bardoxolone) is an oral, once-daily therapy that is being evaluated in the CARDINAL Phase 2/3 clinical trial (NCT03019185) in patients with chronic kidney disease…

Researchers reported the case of a Chinese family who developed Alport syndrome due to a novel mutation in the COL4A4 gene, which was previously unknown to be associated with the disease. Knowing which mutations within the COL4A4 gene lead to Alport syndrome brings valuable insight into the development…